Plant ID: NPO14558
Plant Latin Name: Aquilaria sinensis
Taxonomy Genus: Aquilaria
Taxonomy Family: Thymelaeaceae
NCBI TaxonomyDB:
210372
Plant-of-the-World-Online:
830849-1
China
PTPN1; PTPN11; PTPN6; | |
FAAH; TDP1; TERT; HSD11B1; HSD17B10; CES2; | |
CA2; CA12; CA1; CA9; CA7; CA14; CA5B; | |
PPARA; PPARD; PPARG; | |
ESR1; | |
PLG; | |
TLR2; | |
NFKB1; | |
LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; THPO; |
Cytochrome P450 Enzymes: | CYP3A4; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
Protein Phosphatase | PTPN6 | Protein-tyrosine phosphatase 1C | P29350 | CHEMBL3166 |
Serine protease | PLG | Plasminogen | P00747 | CHEMBL1801 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.867E-13 | 5.299E-09 | CA1, CA12, CA14, CA2, CA5B, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.924E-11 | 7.633E-08 | CA1, CA12, CA2, CA5B, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.685E-08 | 4.176E-05 | CA1, CA12, CA2, CA5B, CA7, CA9, ESR1, PPARA, PPARD, PPARG, PTPN1 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.705E-08 | 8.588E-05 | FABP2, FABP3, FABP4, FABP5 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.093E-06 | 7.002E-04 | ESR1, PPARA, PPARD, PPARG |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.322E-06 | 1.297E-03 | ESR1, PPARA, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:0033277; abortive mitotic cell cycle | 2.493E-06 | 1.357E-03 | PTPN11, PTPN6 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.876E-06 | 2.004E-03 | FABP3, PPARA, PPARD, PPARG |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 4.189E-06 | 2.073E-03 | ESR1, PPARA, TERT |
BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 6.565E-06 | 2.917E-03 | CES2, FAAH, FABP3, PPARA, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.471E-06 | 3.190E-03 | CA2, CA7 |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.121E-05 | 4.521E-03 | FABP3, LMNA, PLG, PPARD, PPARG, PTPN6, TERT, TLR2 |
BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.422E-05 | 5.340E-03 | CA2, CA9, LMNA, MAPT, NFKB1, PPARD, PPARG, PTPN1, PTPN11, TDP1, TERT |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.485E-05 | 8.233E-03 | PPARA, PPARG |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.495E-05 | 8.233E-03 | NFKB1, PPARA, PPARG, PTPN11 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.436E-17 | 1.837E-12 | CA1, CA12, CA14, CA2, CA5B, CA7, CA9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.995E-16 | 1.975E-14 | CA12, CA1, CA5B, CA2, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.048E-11 | 5.186E-10 | FABP2, FABP3, FABP4, FABP5, PPARG, PPARA, PPARD |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.345E-05 | 7.738E-04 | PTPN1, PTPN11, PPARA, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.615E-04 | 4.315E-03 | PTPN6, PTPN11, ESR1, TLR2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 1.720E-04 | 3.858E-03 | PTPN11, PPARA, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.949E-04 | 3.858E-03 | PTPN6, NFKB1, TLR2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 1.849E-03 | 2.614E-02 | THPO, PTPN6, PTPN11 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 2.306E-03 | 2.854E-02 | CYP3A4, CES2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 2.893E-03 | 2.900E-02 | PTPN11, NFKB1, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.519E-03 | 2.900E-02 | NFKB1, PPARD |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; |